MED10 and cancer: Interestingly, and of clinical relevance especially in the context of patient stratification for precision medicine, we demonstrated that targeting MED10 elicits downregulation of hsa-miR-590-5p expression preferentially in metastatic, transitional cell (urothelial) carcinoma cells and significantly attenuates their oncogenicity and metastatic and cancer stemness phenotypes.